{
  "docId": "019de074-5234-763a-a0be-96f5f1aa05d9",
  "docSlug": "9279d19020d2e95032dc34a127aaa2e7",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 40,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Includes a molecular visualization showing the binding site of CTX-471 compared to other antibodies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-5234-763a-a0be-96f5f1aa05d9/30",
  "deckHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9",
  "deckJsonHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9.json",
  "deckAnchorHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.55,
        "x": 0.03,
        "y": 0.19
      },
      "kind": "callout",
      "text": "CTX-471: next generation CD137 agonist",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36587419-418b-45d4-8916-6c141fe0b746",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.55,
        "x": 0.03,
        "y": 0.39
      },
      "kind": "callout",
      "text": "Phase 1 Study Update",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be61214d-7f34-454a-bf3c-5cb4205804d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.65,
        "y": 0.2
      },
      "kind": "image",
      "text": "Molecular structure diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "190fb2be-f63a-4f9a-ac5d-dc5a508817bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.55,
        "x": 0.03,
        "y": 0.47
      },
      "kind": "list",
      "text": "Monotherapy in post checkpoint inhibitor patients\nMonotherapy Phase 1a multiple ascending dose study completed\n- Near PR in a patient with mucosal melanoma\n- Prolonged stable disease in two patients with NSCLC\n- MTD defined by immune thrombocytopenia\nMonotherapy Phase 1b dose expansion study nearing completion\n- 4 PRs observed so far: small cell lung cancer, mucosal melanoma, metastatic melanoma, and mesothelioma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f1e9ddb-7ec7-428f-a807-0754e4d3228a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.03,
        "y": 0.27
      },
      "kind": "paragraph",
      "text": "Fully human, IgG4, optimized affinity for agonistic antibody\nUnique epitope: non-ligand blocking",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29ae4c9e-b441-464a-b4b3-fb01bb4e45ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.65,
        "y": 0.77
      },
      "kind": "source-note",
      "text": "*Eskiocak, et al. JCI Insight. 2020;5(5):e133647",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67ae3a4a-4ca6-4279-ad20-39797d3ddab6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "CTX-471: Potential Best-in-Class CD137 Agonist",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc67f032-d6b1-4307-9342-8b2a9d8027ed",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f0a32b3c-a238-480c-9a9d-c05166154467",
      "evidence": "The document implies that the current state of cancer treatment is inadequate and that innovative therapies are needed.",
      "position": 0,
      "objective": "The cost of inaction in cancer treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 40,
      "from": 7,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "6979bcd9-f71b-4757-b297-1c4753563587",
      "evidence": "The document presents data and results for each of these therapies.",
      "position": 1,
      "objective": "The potential benefits of CTX-009, CTX-471, and CTX-8371",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}